Skip to main content
. 2016 Jun 3;95(22):e3780. doi: 10.1097/MD.0000000000003780

TABLE 1.

Baseline Demographic, Clinical and Laboratory Characteristics of Patients Treated With Tenofovir Plus Emtricitabine or Lamivudine and Either Atazanavir/Ritonavir or Darunavir/Ritonavir or Lopinavir/Ritonavir or a Non-Nucleoside Reverse Transcriptase Inhibitor

graphic file with name medi-95-e3780-g001.jpg